Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma.

Frontiers in immunology - 1 Jan 2021

Zhang Wenjing, Kong Yujia, Li Yuting, Shi Fuyan, Lyu Juncheng, Sheng Chao, Wang Suzhen, Wang Qinghua

Abstract excerpt

Background: Immune checkpoint inhibitor (ICI) therapy dramatically prolongs melanoma survival. Currently, the identified ICI markers are sometimes ineffective. The objective of this study was to identify novel determinants of ICI efficacy. Methods: We comprehensively curated pretreatment somatic mutational profiles and clinical information from 631 melanoma patients who received blockade therapy of immune...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Gene Ontology

Share to Immune Checkpoint Inhibitors

Share to Kaplan-Meier Estimate

Share to Melanoma

Share to Transcriptome

Source

Open in PubMed Open full text

Identifiers

PMID: 35087523
DOI: 10.3389/fimmu.2021.798474
PMCID: PMC8787219

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma.PMID 35087523Read ↗

A mutational signature and significantly mutated driver genes associated with immune checkpoint inhibitor response across multiple cancers.Semantic proximity Read ↗

Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma PatientsSemantic proximity Read ↗

The immune response-related genomic alterations in patients with malignant melanoma.Semantic proximity Read ↗

Genomic and Epigenomic Biomarkers of Immune Checkpoint Immunotherapy Response in Melanoma: Current and Future PerspectivesSemantic proximity Read ↗

Clinical Impact of Immune Checkpoint Inhibitor (ICI) Response, DNA Damage Repair (DDR) Gene Mutations and Immune-Cell Infiltration in Metastatic Melanoma Subtypes.Semantic proximity Read ↗

Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response RatesSemantic proximity Read ↗

Molecular, Genetic Susceptibility and Immunotherapy of MelanomaSemantic proximity Read ↗

Genomic and transcriptomic analyses of melanoma in Japanese patients reveal candidate biomarkers for immune checkpoint inhibitor respondersSemantic proximity Read ↗

Association of EYS mutations with immune checkpoint inhibitor outcome and response in melanoma and non-small cell lung cancerSemantic proximity Read ↗

Biological Pathway-Derived TMB Robustly Predicts the Outcome of Immune Checkpoint Blockade Therapy.Semantic proximity Read ↗

Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.Semantic proximity Read ↗

Molecular Susceptibility and Treatment Challenges in Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.